CMS under Dr. Oz: 20 key actions
CMS Administrator Mehmet Oz, MD, has moved quickly to advance President Donald Trump’s “Make America Healthy Again” agenda in 2025. The push comes after President Trump this summer signed the One Big Beautiful Bill Act, a sweeping package of reforms targeting Medicaid, Medicare and the ACA marketplace. From plans to close a Medicaid funding “loophole” […]
Shake Shack makes menu change that failed at McDonald’s
Comfort. We all seek it, and many try to find it in food. But comfort food often gives only a few minutes of satisfaction before we end up with extra weight, bloating, and a lingering sense of guilt that pulls us back for more. It’s a vicious circle that’s hard to break. If you’re disciplined […]
Multiple Headwinds Affected Diageo plc (DEO) in Q3
Artisan Partners, an investment management company, released its “Artisan Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The equity market rally persisted in the third quarter as investors ignored tariffs, buoyed by strong corporate earnings, rising AI investment, and prospects of economic support from US fiscal policy and […]
People Jabbing Themselves With Black Market “GLP-3” Drugs
Some people are hitting a weight loss plateau with GLP-1 agonist drugs like Ozempic, so they’re turning to a stronger variety that promises even more dramatic weight loss — up to more than 70 pounds in some instances, The Atlantic reports. There’s a small wrinkle: the US Food and Drug Administration has yet to officially […]
Devices Target the Gut to Maintain Weight Loss from GLP-1 Drugs
Christina had tried dieting and exercise before. The weight always came off but then crept back on, especially after she gave birth to her son in 2022. She had hoped that a new class of weight-loss drugs might finally offer something different. Obesity treatments such as Wegovy and Zepbound had just arrived on the scene, […]
Audio long read: Will blockbuster obesity drugs revolutionize addiction treatment?
Anecdotal stories suggesting that weight-loss drugs can help people shake long-standing addictions have been spreading fast in the past few years, through online forums, weight-loss clinics and news headlines. And now, clinical data are starting to back them up. Over a dozen randomized clinical studies testing whether GLP-1 drugs like Ozempic can suppress addiction are […]
IJMS, Vol. 27, Pages 369: More than Dysbiosis: Imbalance in Humoral and Neuronal Bidirectional Crosstalk Between Gut and Brain in Alzheimer’s Disease
IJMS, Vol. 27, Pages 369: More than Dysbiosis: Imbalance in Humoral and Neuronal Bidirectional Crosstalk Between Gut and Brain in Alzheimer’s Disease International Journal of Molecular Sciences doi: 10.3390/ijms27010369 Authors: Gauhar Tassibekova Manzura Zholdassova Nataliia Novosolova Tarja Malm Rashid Giniatullin Almira Kustubayeva The intestinal microbiota, a diverse community of microorganisms residing in the human gut, […]
Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s – Reuters
Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s Reuters Devices Target the Gut to Maintain Weight Loss from GLP-1 Drugs IEEE Spectrum Considering Taking A GLP-1? Here’s How To Protect Your Muscle Mass MindBodyGreen Insight: Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s Yahoo GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market – Global GlobeNewswire
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. This pill, the first GLP-1 tablet specifically cleared for chronic weight management, can materially improve NVO’s long-term profitability and cash flow visibility. Amid an increasingly fierce […]
Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK
We recently published Big Winners: 10 Stocks Refusing to take a Holiday. Novo Nordisk A/S (NYSE:NVO) is one of the last week’s best performers. Novo Nordisk grew its share prices by 8.96 percent week-on-week as investors cheered the approval of the Food and Drug Administration (FDA) for the pill version of its blockbuster weight loss […]